Loading…
Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation
Abstract Background It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx). Objective To describe the clinical characteristics, e...
Saved in:
Published in: | Open forum infectious diseases 2017-10, Vol.4 (suppl_1), p.S702-S702 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | S702 |
container_issue | suppl_1 |
container_start_page | S702 |
container_title | Open forum infectious diseases |
container_volume | 4 |
creator | Mañez, Noelia Alderete, Manuel Benso, Jose Valledor, Alejandra Smud, Astrid Schijman, Alejandro Besuschio, Susana Barcan, Laura |
description | Abstract
Background
It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx).
Objective
To describe the clinical characteristics, evolution, mortality, to evaluate reactivation risk factors and to analyze the usefulness of molecular tests in patients undergoing at SOT with Chagas’ disease risk (ChR) (R or Donor-derived transmission, -DT-), in a hospital in our country.
Methods
Retrospective cohort from all the patients who received an SOT in our hospital from January 1988 to March 2017. All patients with ChR: either R or DT were analyzed. Inclusion: survival more 30 days and 6 months of follow-up or until death. We performed post-Tx monitoring with parasitaemia (Strout), and serial whole blood polymerase chain reaction (PCR) testing, weekly until 2 months, every 2 weeks until the sixth month and monthly until the year, later annual. PCR monitoring is done since 2006.
Results
We performed 1932 SOT in 29 years: 54 SOT in patients with ChR, 46 chagasic recipients (CR) and 8 chagasic donors (CD) to negative recipient 24/46 (52%) presented R, (see Table 1), 4 had more than one episode. Time to first R was 67 days (r = 3–296, median 30 days). At the time of the R Strout was performed in 19 episode 13 were negative, PCR was positive in 10/10 of perfcormed test, 32% vs. 100% (P = 0.001). Clinical R: 5 episode in 4 patients (panniculitis 3, 1 with myocarditis, 1 myocarditis). Strout was negative in 2 of these, in the other episode monitoring had not been performed. Immunosuppression (IS): there were no differences in the IS, (induction and treatment of rejections). Reactivation: 21/24 responded to treatment, 2 spontaneously PCR-negative, 1 died. Mortality: 6/24 (25%) in pt. R and 2/17 (12%) in pt no R (P = ns), not related mortality. DT occurred in 1/ 3 liver and in 0/5 renal recipients.
Type of Tx
All
Reactivation
Clinic
Liver (L)
786
7/26 (27%)
1/7 (14%)
Heart
241
13/23 (56%)
2/13 (15%)
Kidney (K)
613
2/5 (40%)
1/2 (50%)
Lung
105
1/2 (50%)
0
LK
26
1/1 (100%
0
Others
161
0
0
Conclusion
PCR was more sensitive than Strout for detection of R or transmission. There was no clinical R in pt monitored by PCR. Also PCR sensitivity allow safe acceptance of Chagasic organs.
Disclosures
All authors: No reported disclosures. |
doi_str_mv | 10.1093/ofid/ofx163.1883 |
format | article |
fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5631452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ofid/ofx163.1883</oup_id><sourcerecordid>10.1093/ofid/ofx163.1883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1743-4c37172115ea1849c244282494f5e5befd95e039c01d888ab024e6a58e76044c3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMoWGrvHnOXrfncTS6CFD8KxQq255Bms2tkmyzJVrS_3l1WRE9eZgZmnpfhAeASozlGkl6HypV9-cA5nWMh6AmYEEpEJiQvTn_N52CW0htCCGPEUSEn4GkTP1vtwzHsNTTxcHRw6StrOhc8dB4-685Z3yW49aWNdXC-hi-hcSVcx1p7uInap7bRvtMDcgHOKt0kO_vuU7C9v9ssHrPV-mG5uF1lBheMZszQAhcEY241FkwawhgRhElWcct3tiolt4hKg3AphNA7RJjNNRe2yBHr6Sm4GXPbw25vS9O_GHWj2uj2On6qoJ36u_HuVdXhXfGcYsZJH4DGABNDStFWPyxGanCqBqdqdKoGpz1yNSLh0P5__QUCUXvT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation</title><source>OUP_牛津大学出版社OA刊</source><source>PubMed Central</source><creator>Mañez, Noelia ; Alderete, Manuel ; Benso, Jose ; Valledor, Alejandra ; Smud, Astrid ; Schijman, Alejandro ; Besuschio, Susana ; Barcan, Laura</creator><creatorcontrib>Mañez, Noelia ; Alderete, Manuel ; Benso, Jose ; Valledor, Alejandra ; Smud, Astrid ; Schijman, Alejandro ; Besuschio, Susana ; Barcan, Laura</creatorcontrib><description>Abstract
Background
It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx).
Objective
To describe the clinical characteristics, evolution, mortality, to evaluate reactivation risk factors and to analyze the usefulness of molecular tests in patients undergoing at SOT with Chagas’ disease risk (ChR) (R or Donor-derived transmission, -DT-), in a hospital in our country.
Methods
Retrospective cohort from all the patients who received an SOT in our hospital from January 1988 to March 2017. All patients with ChR: either R or DT were analyzed. Inclusion: survival more 30 days and 6 months of follow-up or until death. We performed post-Tx monitoring with parasitaemia (Strout), and serial whole blood polymerase chain reaction (PCR) testing, weekly until 2 months, every 2 weeks until the sixth month and monthly until the year, later annual. PCR monitoring is done since 2006.
Results
We performed 1932 SOT in 29 years: 54 SOT in patients with ChR, 46 chagasic recipients (CR) and 8 chagasic donors (CD) to negative recipient 24/46 (52%) presented R, (see Table 1), 4 had more than one episode. Time to first R was 67 days (r = 3–296, median 30 days). At the time of the R Strout was performed in 19 episode 13 were negative, PCR was positive in 10/10 of perfcormed test, 32% vs. 100% (P = 0.001). Clinical R: 5 episode in 4 patients (panniculitis 3, 1 with myocarditis, 1 myocarditis). Strout was negative in 2 of these, in the other episode monitoring had not been performed. Immunosuppression (IS): there were no differences in the IS, (induction and treatment of rejections). Reactivation: 21/24 responded to treatment, 2 spontaneously PCR-negative, 1 died. Mortality: 6/24 (25%) in pt. R and 2/17 (12%) in pt no R (P = ns), not related mortality. DT occurred in 1/ 3 liver and in 0/5 renal recipients.
Type of Tx
All
Reactivation
Clinic
Liver (L)
786
7/26 (27%)
1/7 (14%)
Heart
241
13/23 (56%)
2/13 (15%)
Kidney (K)
613
2/5 (40%)
1/2 (50%)
Lung
105
1/2 (50%)
0
LK
26
1/1 (100%
0
Others
161
0
0
Conclusion
PCR was more sensitive than Strout for detection of R or transmission. There was no clinical R in pt monitored by PCR. Also PCR sensitivity allow safe acceptance of Chagasic organs.
Disclosures
All authors: No reported disclosures.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofx163.1883</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Abstracts</subject><ispartof>Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S702-S702</ispartof><rights>The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631452/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631452/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1604,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Mañez, Noelia</creatorcontrib><creatorcontrib>Alderete, Manuel</creatorcontrib><creatorcontrib>Benso, Jose</creatorcontrib><creatorcontrib>Valledor, Alejandra</creatorcontrib><creatorcontrib>Smud, Astrid</creatorcontrib><creatorcontrib>Schijman, Alejandro</creatorcontrib><creatorcontrib>Besuschio, Susana</creatorcontrib><creatorcontrib>Barcan, Laura</creatorcontrib><title>Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation</title><title>Open forum infectious diseases</title><description>Abstract
Background
It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx).
Objective
To describe the clinical characteristics, evolution, mortality, to evaluate reactivation risk factors and to analyze the usefulness of molecular tests in patients undergoing at SOT with Chagas’ disease risk (ChR) (R or Donor-derived transmission, -DT-), in a hospital in our country.
Methods
Retrospective cohort from all the patients who received an SOT in our hospital from January 1988 to March 2017. All patients with ChR: either R or DT were analyzed. Inclusion: survival more 30 days and 6 months of follow-up or until death. We performed post-Tx monitoring with parasitaemia (Strout), and serial whole blood polymerase chain reaction (PCR) testing, weekly until 2 months, every 2 weeks until the sixth month and monthly until the year, later annual. PCR monitoring is done since 2006.
Results
We performed 1932 SOT in 29 years: 54 SOT in patients with ChR, 46 chagasic recipients (CR) and 8 chagasic donors (CD) to negative recipient 24/46 (52%) presented R, (see Table 1), 4 had more than one episode. Time to first R was 67 days (r = 3–296, median 30 days). At the time of the R Strout was performed in 19 episode 13 were negative, PCR was positive in 10/10 of perfcormed test, 32% vs. 100% (P = 0.001). Clinical R: 5 episode in 4 patients (panniculitis 3, 1 with myocarditis, 1 myocarditis). Strout was negative in 2 of these, in the other episode monitoring had not been performed. Immunosuppression (IS): there were no differences in the IS, (induction and treatment of rejections). Reactivation: 21/24 responded to treatment, 2 spontaneously PCR-negative, 1 died. Mortality: 6/24 (25%) in pt. R and 2/17 (12%) in pt no R (P = ns), not related mortality. DT occurred in 1/ 3 liver and in 0/5 renal recipients.
Type of Tx
All
Reactivation
Clinic
Liver (L)
786
7/26 (27%)
1/7 (14%)
Heart
241
13/23 (56%)
2/13 (15%)
Kidney (K)
613
2/5 (40%)
1/2 (50%)
Lung
105
1/2 (50%)
0
LK
26
1/1 (100%
0
Others
161
0
0
Conclusion
PCR was more sensitive than Strout for detection of R or transmission. There was no clinical R in pt monitored by PCR. Also PCR sensitivity allow safe acceptance of Chagasic organs.
Disclosures
All authors: No reported disclosures.</description><subject>Abstracts</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqFkE1LAzEQhoMoWGrvHnOXrfncTS6CFD8KxQq255Bms2tkmyzJVrS_3l1WRE9eZgZmnpfhAeASozlGkl6HypV9-cA5nWMh6AmYEEpEJiQvTn_N52CW0htCCGPEUSEn4GkTP1vtwzHsNTTxcHRw6StrOhc8dB4-685Z3yW49aWNdXC-hi-hcSVcx1p7uInap7bRvtMDcgHOKt0kO_vuU7C9v9ssHrPV-mG5uF1lBheMZszQAhcEY241FkwawhgRhElWcct3tiolt4hKg3AphNA7RJjNNRe2yBHr6Sm4GXPbw25vS9O_GHWj2uj2On6qoJ36u_HuVdXhXfGcYsZJH4DGABNDStFWPyxGanCqBqdqdKoGpz1yNSLh0P5__QUCUXvT</recordid><startdate>20171004</startdate><enddate>20171004</enddate><creator>Mañez, Noelia</creator><creator>Alderete, Manuel</creator><creator>Benso, Jose</creator><creator>Valledor, Alejandra</creator><creator>Smud, Astrid</creator><creator>Schijman, Alejandro</creator><creator>Besuschio, Susana</creator><creator>Barcan, Laura</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20171004</creationdate><title>Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation</title><author>Mañez, Noelia ; Alderete, Manuel ; Benso, Jose ; Valledor, Alejandra ; Smud, Astrid ; Schijman, Alejandro ; Besuschio, Susana ; Barcan, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1743-4c37172115ea1849c244282494f5e5befd95e039c01d888ab024e6a58e76044c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Abstracts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mañez, Noelia</creatorcontrib><creatorcontrib>Alderete, Manuel</creatorcontrib><creatorcontrib>Benso, Jose</creatorcontrib><creatorcontrib>Valledor, Alejandra</creatorcontrib><creatorcontrib>Smud, Astrid</creatorcontrib><creatorcontrib>Schijman, Alejandro</creatorcontrib><creatorcontrib>Besuschio, Susana</creatorcontrib><creatorcontrib>Barcan, Laura</creatorcontrib><collection>OUP_牛津大学出版社OA刊</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mañez, Noelia</au><au>Alderete, Manuel</au><au>Benso, Jose</au><au>Valledor, Alejandra</au><au>Smud, Astrid</au><au>Schijman, Alejandro</au><au>Besuschio, Susana</au><au>Barcan, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation</atitle><jtitle>Open forum infectious diseases</jtitle><date>2017-10-04</date><risdate>2017</risdate><volume>4</volume><issue>suppl_1</issue><spage>S702</spage><epage>S702</epage><pages>S702-S702</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract
Background
It is estimated that 1.5 million people are infected with T. cruzi in Argentina (4%). Chagas reactivation rate (R) in patients with solid organ transplantation (SOT) is around 33%, being higher in cardiac transplantation (Tx).
Objective
To describe the clinical characteristics, evolution, mortality, to evaluate reactivation risk factors and to analyze the usefulness of molecular tests in patients undergoing at SOT with Chagas’ disease risk (ChR) (R or Donor-derived transmission, -DT-), in a hospital in our country.
Methods
Retrospective cohort from all the patients who received an SOT in our hospital from January 1988 to March 2017. All patients with ChR: either R or DT were analyzed. Inclusion: survival more 30 days and 6 months of follow-up or until death. We performed post-Tx monitoring with parasitaemia (Strout), and serial whole blood polymerase chain reaction (PCR) testing, weekly until 2 months, every 2 weeks until the sixth month and monthly until the year, later annual. PCR monitoring is done since 2006.
Results
We performed 1932 SOT in 29 years: 54 SOT in patients with ChR, 46 chagasic recipients (CR) and 8 chagasic donors (CD) to negative recipient 24/46 (52%) presented R, (see Table 1), 4 had more than one episode. Time to first R was 67 days (r = 3–296, median 30 days). At the time of the R Strout was performed in 19 episode 13 were negative, PCR was positive in 10/10 of perfcormed test, 32% vs. 100% (P = 0.001). Clinical R: 5 episode in 4 patients (panniculitis 3, 1 with myocarditis, 1 myocarditis). Strout was negative in 2 of these, in the other episode monitoring had not been performed. Immunosuppression (IS): there were no differences in the IS, (induction and treatment of rejections). Reactivation: 21/24 responded to treatment, 2 spontaneously PCR-negative, 1 died. Mortality: 6/24 (25%) in pt. R and 2/17 (12%) in pt no R (P = ns), not related mortality. DT occurred in 1/ 3 liver and in 0/5 renal recipients.
Type of Tx
All
Reactivation
Clinic
Liver (L)
786
7/26 (27%)
1/7 (14%)
Heart
241
13/23 (56%)
2/13 (15%)
Kidney (K)
613
2/5 (40%)
1/2 (50%)
Lung
105
1/2 (50%)
0
LK
26
1/1 (100%
0
Others
161
0
0
Conclusion
PCR was more sensitive than Strout for detection of R or transmission. There was no clinical R in pt monitored by PCR. Also PCR sensitivity allow safe acceptance of Chagasic organs.
Disclosures
All authors: No reported disclosures.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ofid/ofx163.1883</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2328-8957 |
ispartof | Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S702-S702 |
issn | 2328-8957 2328-8957 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5631452 |
source | OUP_牛津大学出版社OA刊; PubMed Central |
subjects | Abstracts |
title | Trypanozoma cruzi Infection in Patients Undergoing Solid Organ Transplantation |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T09%3A33%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trypanozoma%20cruzi%20Infection%20in%20Patients%20Undergoing%20Solid%20Organ%20Transplantation&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Ma%C3%B1ez,%20Noelia&rft.date=2017-10-04&rft.volume=4&rft.issue=suppl_1&rft.spage=S702&rft.epage=S702&rft.pages=S702-S702&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofx163.1883&rft_dat=%3Coup_pubme%3E10.1093/ofid/ofx163.1883%3C/oup_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1743-4c37172115ea1849c244282494f5e5befd95e039c01d888ab024e6a58e76044c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ofid/ofx163.1883&rfr_iscdi=true |